These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 35897036)

  • 1. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment.
    Ma G; Zhang Z; Li P; Zhang Z; Zeng M; Liang Z; Li D; Wang L; Chen Y; Liang Y; Niu H
    Cell Commun Signal; 2022 Jul; 20(1):114. PubMed ID: 35897036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PD-L1-targeting Regulator for Metabolic Reprogramming to Enhance Glutamine Inhibition-Mediated Synergistic Antitumor Metabolic and Immune Therapy.
    Jin XK; Zhang SM; Liang JL; Zhang SK; Qin YT; Huang QX; Liu CJ; Zhang XZ
    Adv Mater; 2024 Feb; 36(6):e2309094. PubMed ID: 38014890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies.
    Ma G; Li C; Zhang Z; Liang Y; Liang Z; Chen Y; Wang L; Li D; Zeng M; Shan W; Niu H
    Front Oncol; 2021; 11():697894. PubMed ID: 34327138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.
    Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J
    Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.
    Li D; Cao D; Sun Y; Cui Y; Zhang Y; Jiang J; Cao X
    Front Immunol; 2024; 15():1331641. PubMed ID: 38348027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cancer metabolic reprogramming and immune response.
    Xia L; Oyang L; Lin J; Tan S; Han Y; Wu N; Yi P; Tang L; Pan Q; Rao S; Liang J; Tang Y; Su M; Luo X; Yang Y; Shi Y; Wang H; Zhou Y; Liao Q
    Mol Cancer; 2021 Feb; 20(1):28. PubMed ID: 33546704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-sensitive tumor-tropism hybrid membrane-coated nanoparticles for reprogramming the tumor microenvironment and boosting the antitumor immunity.
    Zhang J; Wei L; Ma X; Wang J; Liang S; Chen K; Wu M; Niu L; Zhang Y
    Acta Biomater; 2023 Aug; 166():470-484. PubMed ID: 37253416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy.
    Nicolini A; Ferrari P
    Front Immunol; 2024; 15():1353787. PubMed ID: 39119332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy.
    Lim SA
    BMB Rep; 2024 Sep; 57(9):388-399. PubMed ID: 38919017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting metabolism to enhance immunotherapy within tumor microenvironment.
    Liang XH; Chen XY; Yan Y; Cheng AY; Lin JY; Jiang YX; Chen HZ; Jin JM; Luan X
    Acta Pharmacol Sin; 2024 Oct; 45(10):2011-2022. PubMed ID: 38811773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective.
    Liu J; Bai Y; Li Y; Li X; Luo K
    EBioMedicine; 2024 Sep; 107():105301. PubMed ID: 39178747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of lipid metabolic reprogramming in tumor microenvironment.
    Yang K; Wang X; Song C; He Z; Wang R; Xu Y; Jiang G; Wan Y; Mei J; Mao W
    Theranostics; 2023; 13(6):1774-1808. PubMed ID: 37064872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-programmed nutrient partitioning in the tumour microenvironment.
    Reinfeld BI; Madden MZ; Wolf MM; Chytil A; Bader JE; Patterson AR; Sugiura A; Cohen AS; Ali A; Do BT; Muir A; Lewis CA; Hongo RA; Young KL; Brown RE; Todd VM; Huffstater T; Abraham A; O'Neil RT; Wilson MH; Xin F; Tantawy MN; Merryman WD; Johnson RW; Williams CS; Mason EF; Mason FM; Beckermann KE; Vander Heiden MG; Manning HC; Rathmell JC; Rathmell WK
    Nature; 2021 May; 593(7858):282-288. PubMed ID: 33828302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral lipid metabolic reprogramming as a pro-tumoral regulator in the tumor milieu.
    Wang R; Hu Q; Wu Y; Guan N; Han X; Guan X
    Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188962. PubMed ID: 37541532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomimetic Nanoplatform Loading Type I Aggregation-Induced Emission Photosensitizer and Glutamine Blockade to Regulate Nutrient Partitioning for Enhancing Antitumor Immunotherapy.
    Xie W; Chen B; Wen H; Xiao P; Wang L; Liu W; Wang D; Tang BZ
    ACS Nano; 2022 Jul; 16(7):10742-10753. PubMed ID: 35830505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Aspects of Cancer Cell Metabolism.
    Ucche S; Hayakawa Y
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
    Bahrambeigi S; Shafiei-Irannejad V
    Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Tumor Metabolic Reprogramming in Tumor Immunity.
    Zhang X; Song W; Gao Y; Zhang Y; Zhao Y; Hao S; Ni T
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
    Huang L; Xu H; Peng G
    Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.